← Back to all trials
Completed
NCT07606820
Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea
Conditions: Rosacea
Sex: All
Ages: 18 Years – 60 Years
Healthy volunteers: No
Phase: NA
Enrollment: 30
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Location: Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China Nanjing Jiangsu
Summary
A Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of rosacea according to the criteria established by the ROSacea COnsensus (ROSCO) 2019 guidelines.
* Presence of obvious facial erythema accompanied by significant burning and tingling sensations, with subjective symptoms (e.g., burning and tingling) being more severe than the observable clinical signs.
* Refractory facial erythema despite conventional treatment, including antibiotics (metronidazole, doxycycline, and minocycline), oral isotretinoin, and oral beta-blockers.
Exclusion Criteria:
* Facial inflammatory dermatoses such as acne, contact dermatitis, seborrheic dermatitis, or other facial skin diseases.
* Pregnancy or lactation.
* Hepatic or renal insufficiency.
* Ongoing treatment with long-term topical glucocorticoids or retinoids.
Source: ClinicalTrials.gov (NCT07606820). StuddyBuddy aggregates publicly available trial information.
